Jacob Van Naarden, Loxo COO (Loxo)
December 5, 2020 12:30 PM ESTUpdated December 7, 10:00 AM
R&D

#ASH20 Loxo and Eli Lil­ly show off PhI/II da­ta for their BTK in­hibitor in two blood can­cers

Max Gelman

Senior Editor

ASH is back and Loxo is primed and ready to present new da­ta that they think will be quite ex­cit­ing.

The Lil­ly-owned com­pa­ny is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times